Clinical trials: Advanced Solid Tumors (Phase 1)
Advanced Solid Tumor
A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.
To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SPH6516 tablets in the treatment of advanced solid tumors.
- Trial name
- NCT06266923
- Testing
- SPH6516 tablets
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Medical Oncology
Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole
Characterize the safety, tolerability, ECG effects, pharmacokinetics and immunogenicity of anetumab ravtansine given as single agent and after inhibition of CYP3A4 and P-gp by concomitant administration of itraconazole in…
- Trial name
- NCT02824042
- Testing
- Anetumab ravtansine (BAY94-9343), Itraconazole
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 63 people
- Sponsor
- Bayer
Solid Tumor
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
This is a Phase 1 dose-escalation and expansion study that will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of SAIL66 in patients with CLDN6-positive locally advanced…
- Trial name
- NCT05735366
- Testing
- SAIL66
- Where
- 9 sites in United States, Japan
- Volunteers
- 22 people
- Sponsor
- Chugai Pharmaceutical
Adult Solid Neoplasm
Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
Phase I trial to study the effectiveness of combining erlotinib hydrochloride with irinotecan hydrochloride in treating patients who have advanced solid tumors.
- Trial name
- NCT00045201
- Testing
- Erlotinib Hydrochloride, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Gastric Cancer
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer
- Trial name
- NCT05233436
- Testing
- PF-07265028, Sasanlimab
- Where
- 8 sites in United States, Japan
- Volunteers
- 21 people
- Sponsor
- Pfizer
Advanced Solid Tumors
Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Cisplatin in Patients with Advanced Solid Tumors to determine the recommended dose (RD) of PM01183 in combination with cisplatin, to characterize…
- Trial name
- NCT01980667
- Testing
- lurbinectedin (PM01183), Cisplatin
- Where
- 3 sites in Switzerland, United Kingdom
- Volunteers
- 41 people
- Sponsor
- PharmaMar
Neoplasms
Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
The primary purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of CMD-193 administered intravenously (IV) to subjects with advanced malignant tumors.
- Trial name
- NCT00257881
- Testing
- CMD-193
- Where
- 2 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
Breast Neoplasms, Ovarian Neoplasms
Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
The primary purpose of this study is to evaluate the safety, toxicities, and dosage for investigational drug Motexafin Gadolinium administered with docetaxel to patients with advanced solid tumors.
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms
- Trial name
- NCT00080041
- Testing
- Motexafin Gadolinium Injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Pharmacyclics LLC.
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.
- Trial name
- NCT04380753
- Testing
- AMG 510
- Where
- 4 sites in Hong Kong, Taiwan
- Volunteers
- 12 people
- Sponsor
- Amgen
KRAS P.G12C
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001…
- Trial name
- NCT05410145
- Testing
- D3S-001, Pembrolizumab, Cisplatin
- Where
- 52 sites in United States, Australia and 8 more
- Volunteers
- 442 people
- Sponsor
- D3 Bio (Wuxi) Co., Ltd
Advanced Solid Tumors
A Study in Adult Subjects With Select Advanced Solid Tumors
To evaluate the safety and tolerability of MEDI1873 in adult subjects with selected advanced solid tumors.
- Trial name
- NCT02583165
- Testing
- MEDI1873
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- MedImmune LLC
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy and in combination with other cancer therapies in adult study participants with advanced or metastatic solid tumors.
- Trial name
- ORCHID-1 (NCT05716295)
- Testing
- MDK-703, Checkpoint Inhibitor, Immune
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Medikine, Inc.
Advanced Solid Tumors, HCC
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
This study is an open-label, multi-centre, single-arm, phase I clinical study, to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of IMM2510 (an anti-PD-L1/VEGF bispecific antibody…
- Trial name
- NCT06764836
- Testing
- IMM27M, IMM2510
- Where
- China
- Volunteers
- 108 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, NSCLC
- Trial name
- NCT05753722
- Testing
- PRTH-101, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 79 people
- Sponsor
- Incendia Therapeutics
Breast Cancer, Cholangiocarcinoma
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion.
- Conditions
- Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
- Trial name
- STARTRK-2 (NCT02568267)
- Testing
- Entrectinib
- Where
- 120 sites in United States, Australia and 14 more
- Volunteers
- 534 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors (Phase 1), Mesothelioma
Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if drug AROG4-01 is safe in patients with solid tumors who have no available treatment alternative. Different doses will be tested in order to identify the most suitable one.
- Conditions
- Solid Tumors (Phase 1), Mesothelioma, Colorectal Carcinoma, Ovarian Cancer
- Trial name
- AROG4-01-01 (NCT06652529)
- Testing
- AROG4-01
- Volunteers
- 35 people
- Sponsor
- Aromics Therapeutics
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Advanced Solid Tumor
The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies
This is a first-in-human, multicenter, open-label, multiple-dose Phase I study to investigate the safety, tolerability, and initial efficacy of HX009 in subjects with advanced malignant tumors.
- Trial name
- NCT04097769
- Testing
- HX009
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- Waterstone Hanxbio Pty Ltd
Cancer, Neoplasms, Tumors
Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001)
This study will investigate the safety, side effects and how well the body tolerates MK-5108 as well as determine different doses of MK-5108 in participants with advanced and/or refractory solid tumors.
- Trial name
- NCT00543387
- Testing
- MK-5108, docetaxel
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.